Search

Search Constraints

You searched for: Author/Creator Tarquini, P.

Search Results

2. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. (17th December 2015)

4. Daclatasvir/sofosbuvir and ribavirin 800 mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience. Issue 1 (16th February 2017)

5. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies. Issue 1 (16th February 2017)

9. HycycleS: a project on nuclear and solar hydrogen production by sulphur-based thermochemical cycles. (1st January 2011)

10. Impact of different Sofosbuvir-based direct acting antiviral (DAA) regimen in elderly cirrhotic patients: A real world experience from CLEO Group. (10th February 2016)